Intuitive Surgical, Inc. (ISRG)
Trump's Tariffs Could Impact This Top Growth Stock. Here's Why It's Still a Buy
President Donald Trump's macroeconomic policies are creating significant uncertainty. His decision to impose sweeping tariffs on goods imported into the U.S. could harm the economy and specific corporations in ways that are scaring off investors.
ISRG vs. SYK: Which Robotic-Device Innovator Is a Better Buy?
As robotic-assisted surgery becomes a cornerstone of modern healthcare, two medtech giants — Intuitive Surgical ISRG and Stryker SYK — are leading the charge. Intuitive, the pioneer behind the da Vinci Surgical System, has long dominated soft tissue procedures.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Intuitive Surgical: Decent Results But Waiting For An Entry Point
Intuitive Surgical's Q1 2025 earnings showed mixed results, with revenue and EPS beating expectations, but gross margins impacted by tariffs and a lower-margin product mix. Procedure volume growth was strong, especially outside the US, and management raised full-year growth targets, indicating optimism despite macroeconomic uncertainties. The company's valuation is high, trading at 60x forward P/E, making it expensive; I'm looking for a lower entry point around 45x forward P/E.
Is Intuitive Surgical Stock a Buy?
Intuitive Surgical (ISRG 2.05%) has rewarded long-term investors by climbing nearly 200% over the past five years. This is thanks to the company's leadership in a hot growth area: robotic surgery.
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Intuitive Surgical, Inc. (ISRG) Q1 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q1 2025 Earnings Conference Call April 22, 2025 4:30 AM ET Company Participants Dan Connally - Head of IR Gary Guthart - CEO David Rosa - President Jamie Samath - CFO Daniel Oh - Senior Medical Officer Conference Call Participants Travis Steed - Bank of America Securities Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Rick Wise - Stifel Adam Maeder - Piper Sandler Ryan Zimmerman - BTIG David Roman - Goldman Sachs Operator Thank you for standing by, and welcome to the Intuitive Surgical, Inc.'s First Quarter 2025 Earnings Release. [Operator Instructions] As a reminder, today's program is being recorded.
Intuitive Surgical (ISRG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Beat Estimates
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.50 per share a year ago.
Intuitive Surgical beats quarterly results, raises tariff concerns
Intuitive Surgical raised concerns on Tuesday about the potential impact of tariffs on its annual results, despite exceeding Wall Street's first-quarter profit and revenue estimates.
ISRG Q1 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
Intuitive Surgical's first-quarter results are likely to reflect solid performance in the company???s Instruments & Accessories segment.
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
